0000000000079892

AUTHOR

R. Black

showing 7 related works from this author

A measurement of the phases of the CP-violating amplitudes in K0→2π decays and a test of CPT invariance

1990

Abstract The phases of the CP-violating amplitudes in K0→π+π− and K0→2π0 decays, φ+−=46.9°±2.2° and φ00=47.1°±2.8°, have been measured in the same experiment, and a direct comparison gives the phase difference φ00−φ+−=0.2°±2.9°. This result leads to an upper limit on possible CPT violation in the K0 mass matrix, of |(m K 0 −m K 0 )/m K 0 | −18 at the 95% confidence level and is the most stringent test of the equality of particle and antiparticle masses.

Phase differencePhysicsNuclear physicsNuclear and High Energy PhysicsParticle physicsAntiparticleAmplitudeCPT symmetryCP violationLimit (mathematics)Mass matrixlcsh:Physicslcsh:QC1-999Physics Letters B
researchProduct

Observation of the decay KL→π0γγ

1990

Abstract The decay mode K L → π 0 γγ has been observed with a signal of 21 events and an expected background of 1.5±0.9 events. A branching ratio for decays with invariant γγ masses above 280 MeV of (2.1±0.6)×10 −6 is calculated. This result is compared with the values estimated from theoretical models and has implications for the CP conserving contribution to K L → π 0 e + e − decay.

Nuclear physicsPhysicsNuclear and High Energy PhysicsAngular distributionBranching fractionTheoretical modelsAtomic physics
researchProduct

FIRST EVIDENCE FOR DIRECT CP VIOLATION

1989

PhysicsParticle physicsLarge Hadron ColliderCP violation
researchProduct

Measurement of the rate of the decay KL→e+e−γ and observation of a form factor in this decay

1990

Abstract A large sample of Dalitz decays, K L → e + e − γ , has been observed. The branching ratio is Γ(K L →e + e − γ) Γ(K L → all )=(9.2±0.5±0.5)×10 −6 in good agreement with theoretical predictions. We observe an enhancement at high masses in the distribution of the invariant electron-positron pair mass, compared to the distribution expected from QED. This excess is interpreted as being due to virtual mesons contributing to the photon propagator.

Nuclear physicsPhysicsNuclear and High Energy PhysicsPhotonMesonBranching fractionPropagatorHigh Energy Physics::ExperimentLarge samplePhysics Letters B
researchProduct

Search for a neutral Higgs particle in the decay sequence $K^{0}_{L} \to \pi^{0}H^{0}$ and $H^{0} \to e^{+}e^{-}$

1990

Abstract We have searched for the sequence of decays K L 0 → π 0 H 0 and H 0 →e + e − at the CERN Super Proton Synchrotron (SPS), and have allowed for a non-zero H 0 lifetime. Three candidates have been seen, consistent with an expected background of 3.3. Limits on the branching ratio product in the range 10 −8 –10 −7 are presented as a function of the mass and lifetime of the H 0 . These can be used to restrict the neutral Higgs of the minimal standard model.

PhysicsNuclear and High Energy PhysicsSequenceParticle physicsRange (particle radiation)Large Hadron ColliderBranching fractionElementary particleSuper Proton SynchrotronStandard ModelNuclear physicsHiggs bosonHigh Energy Physics::ExperimentParticle Physics - Experiment
researchProduct

Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study.

2019

Purpose: With better access to early diagnosis and appropriate treatment, cervical cancer (CC) burden decreased in several European countries. In Eastern European (EE) countries, which accessed European Union in 2004, CC survival was worse than in the rest of Europe. The present study investigates CC survival differences across five European regions, considering stage at diagnosis (local, regional and metastatic), morphology (mainly squamous versus glandular tumours) and patients’ age. Methods: We analysed 101,714 CC women diagnosed in 2000–2007 and followed-up to December 2008. Age-standardised 5-year relative survival (RS) and the excess risks of cancer death in the 5 years after diagnosi…

MorphologyAdultMaleStage at diagnosiSurvivalAdolescentSocio-culturaleUterine Cervical NeoplasmsDiseaseSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineMedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionSurvival ratePopulation-based studymedia_commonAgedRetrospective StudiesCervical cancerAged 80 and overCervical cancer Europe Morphology Population-based study Stage at diagnosis Survival030219 obstetrics & reproductive medicineRelative survivalbusiness.industryAbsolute risk reductionObstetrics and GynecologyRetrospective cohort studyStage at diagnosisGeneral MedicineMiddle Agedmedicine.diseaseEuropeEastern europeanSurvival Rate030220 oncology & carcinogenesisCervical cancerFemalebusinessDemographyArchives of gynecology and obstetricsReferences
researchProduct

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

2016

Abstract Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-sp…

0301 basic medicineOncologySettore MED/42 - Igiene Generale E Applicata0302 clinical medicinemorphology80 and overStage (cooking)Aged 80 and overOvarian Neoplasmseducation.field_of_studyepidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and GynecologyObstetrics and Gynecologyepidemiology; histology; morphology; ovarian cancer; stage; survivalMiddle AgedTransitional cell carcinomaovarian cancerOncology030220 oncology & carcinogenesisClear cell carcinomaepidemiologyFemaleHumanAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturalesurvivalArticlehistology03 medical and health sciencesInternal medicinemedicineHumansovarian cancer epidemiology survival stage morphology histologyeducationepidemiology ; histology ; morphology ; ovarian cancer ; stage ; survivalCancer stagingAgedNeoplasm StagingGynecologybusiness.industryOvarian NeoplasmCancermedicine.diseasestageCancer registry030104 developmental biologyOvarian cancerbusiness
researchProduct